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Abstract
Background: In people with chronic obstructive pulmonary disease (COPD), limb-muscle dysfunction is one of the
most troublesome systemic manifestations of the disease, which at the functional level is evidenced by reduced
strength and endurance of limb muscles. Improving limb-muscle function is an important therapeutic goal of COPD
management, for which resistance training is recommended. However, current guidelines for resistance training in
COPD mainly focus on improving muscle strength which only reflects one aspect of limb-muscle function and does
not address the issue of reduced muscle endurance. The latter is of importance considering that the reduction in
limb-muscle endurance often is greater than that of muscle weakness, and also, limb-muscle endurance seems to
be closer related to walking capacity as well as arm function than to limb-muscle strength within this group of
people. Thus, strategies targeting multiple aspects of the decreased muscle function are warranted to increase the
possibility for an optimal effect for the individual patient. Periodized resistance training, which represents a planned
variation of resistance training variables (i.e., volume, intensity, frequency, etc.), is one strategy that could be used to
target limb-muscle strength as well as limb-muscle endurance within the same exercise regimen.
Methods: This is an international, multicenter, randomized controlled trial comparing the effect and feasibility of
non-linear periodized resistance training to traditional non-periodized resistance training in people with COPD.
Primary outcomes are dynamic limb-muscle strength and endurance. Secondary outcomes include static limb-
muscle strength and endurance, functional performance, quality of life, dyspnea, intramuscular adaptations as well
as the proportion of responders. Feasibility of the training programs will be assessed and compared on attendance
rate, duration, satisfaction, drop-outs as well as occurrence and severity of any adverse events.
Discussion: The proposed trial will provide new knowledge to this research area by investigating and comparing
the feasibility and effects of non-linear periodized resistance training compared to traditional non-periodized
resistance training. If the former strategy produces larger physiological adaptations than non-periodized resistance
training, this project may influence the prescription of resistance training in people with COPD.
Trial registration: ClinicalTrials.gov, ID: NCT03518723. Registered on 13 April 2018.
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Background
Chronic obstructive pulmonary disease (COPD) is cur-
rently the fourth leading cause of mortality worldwide
and is expected to become the third by 2020. COPD is
now considered a multisystem disease, including
limb-muscle dysfunction [1]. Limb-muscle dysfunction
is considered one of the most troublesome systemic
manifestations of the disease and is characterized by
limb-muscle atrophy and by a fiber-type shift toward a
less oxidative phenotype, which at the functional level is
evidenced by reduced strength and endurance [1, 2]. Im-
portantly, this is negatively associated with clinically
relevant outcomes such as exercise tolerance [3], func-
tional capacity [4], daily life activity [5], as well as in-
creased health care service use, dyspnea and poor
quality of life [6]. Limb-muscle dysfunction is also
closely linked to the prognosis of the disease [7]. For ex-
ample, a mid-thigh muscle cross-sectional area less than
70 cm2 is associated with fourfold increase in mortality
after adjusting for age, sex and FEV1 (1), while each 10%
increment of a quadriceps strength (kg) to body mass
index (kg/m2) ratio is associated to a 9% reduction in
mortality [1, 7].
Limb-muscle dysfunction is a heterogeneous process
in patients with COPD [8] but this is rarely considered
in the exercise training prescription. To date, if the goal
is to improve limb-muscle function, a resistance-training
strategy is often recommended before other available ex-
ercise modalities for people with COPD [9]. For ex-
ample, larger effects on muscle strength are obtained
with resistance training in comparison to whole body
aerobic training or when resistance training is added to
an aerobic training protocol [9–11]. However, the opti-
mal resistance training prescription for people with
COPD with regard to improving either limb-muscle
strength or endurance has yet to be determined [9].
Current guidelines for resistance training in COPD [9]
mainly focus on improving muscle strength which only
reflects one aspect of limb-muscle function and does not
address the issue of reduced muscle endurance. This is
important because the reduction in limb-muscle endur-
ance is often greater than that of muscle weakness, ap-
proximating 32 to 77% in patients with COPD [1, 2].
Limb-muscle endurance also seem to be more closely re-
lated to walking capacity as well as arm function than
muscle strength in COPD [11, 12]. Thus, improving
limb-muscle endurance in patients with COPD should
not be neglected in designing resistance training interven-
tions. Furthermore, resistance training performed in ac-
cordance to current guidelines also lack a clear structure
on how to individualize training schemes. This is of im-
portance as up to 50% of patients with COPD are consid-
ered non-responders after exercise training [13–15]. The
consensus is that the same training schedules cannot be
used for all subjects, even if the goal is the same. Strategies
on how to adapt and vary training schemes based on the
individual condition, preferably targeting multiple aspects
of the decreased muscle function, is warranted to increase
the possibility for an optimal effect for the individual pa-
tient [16, 17]. This calls for alternative ways of performing
resistance training in COPD.
Periodized resistance training, which represents a
planned variation of resistance training variables (i.e.,
volume, intensity, frequency, etc.), is one strategy that
could be used to target muscle strength as well as
muscle endurance within the same exercise regimen. In
healthy adults, periodized resistance training increases
muscle strength as well as muscle power significantly
more than traditional non-periodized resistance training
(RT) [18]. In people with COPD, non-linear periodized
aerobic training has resulted in greater effects on exer-
cise capacity as well as quality of life in comparison to
traditional aerobic training [17]. However, the potential
effect of utilizing the concept of non-linear periodization
of training variables during resistance training in people
with COPD is less investigated.
Therefore, we intend to perform a trial to investigate
the effect and feasibility of non-linear periodized resist-
ance training (NLPRT) compared to traditional RT for
people with COPD.
Primary objective
1. To compare the effect of NLPRT with RT on
isotonic upper (chest press, shoulder flexion) and
lower (leg press, calf press) limb-muscle strength
and limb-muscle endurance in people with COPD.
Hypothesis: NLPRT will result in a similar effect size
with regard to isotonic leg press, chest press, calf
press and shoulder flexion muscle strength but in a
larger effect size (> 1.16) with regard to muscle
endurance than traditional RT at week 9
Secondary objectives
2. To compare the effect of NLPRT and RT on (1)
functional performance measured with the
endurance shuttle walk test (ESWT), the 60-s Sit to
Stand Test (60STS) and the Unsupported Upper
Limb Exercise Test (UULEX), (2) isometric quadri-
ceps muscle strength and endurance, (3) health-
related, disease-specific quality of life (HRQoL), (4)
dyspnea and (5) the proportion of responders for
each of these variables (a response being defined as
an improvement that is larger than the known min-
imal detectable change/or minimal important differ-
ence for a given variable).
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Hypothesis: NLPRT will result in a greater gain on
functional performance, isometric quadriceps muscle
endurance, HRQoL dyspnea, as well as a larger
number of responders while effects will be similar
with regard to isometric muscle strength at week 9
3. To determine the feasibility of NLPRT compared to
RT on attendance rate, duration, satisfaction, drop-
outs as well as occurrence and severity of any ad-
verse events.
Hypothesis: that NLPRT will be feasible to the same
extent as RT over 8 weeks of training
4. To determine the responsiveness of isometric
quadriceps strength and endurance measurement to
NLPRT and RT.
Hypothesis: isometric quadriceps muscle strength
measurements will be highly responsive to NLPRT
as well as RT represented by a standardized
response mean (SRM) > 0.80, while quadriceps
endurance measurements will be highly responsive
to NLPRT but moderately responsive to RT (SRM
0.50 > 0.80) at week 9
5. To explore the intramuscular adaptations of NLPRT
compared to the intramuscular adaptations of RT
Hypothesis: NLPRT will result in a larger increase in
muscle capillarization as well as in the activity of
citrate synthase (CS) and lactate dehydrogenase
(LDH) compared to RT at week 9
Methods
The study is a prospective, assessor-blind, parallel-group,
randomized controlled, multicenter trial with a pre- and
post-intervention design performed at one Swedish center:
Department of Community Medicine and Rehabilitation,
Physiotherapy, Umeå University, Umeå, Sweden (site in-
vestigators AN and EF), one Canadian center: Institut
Universitaire de Cardiologie et de Pneumologie de Québe-
c-Université Laval, Québec City, QC, Canada, (site investi-
gators: DS and FM) and two centers in the Netherlands,
Nijmegen (site investigator: WHvH) and at Hilversum (site
investigator: PK). The test centers are (or resemble) a train-
ing facility for intensive pulmonary rehabilitation with edu-
cated staff present at all times. This protocol is reported in
line with the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) guidelines [19] using the
SPIRIT Figure (Fig. 1), participant flow diagram (Fig. 2) and
Checklist (Additional file 1) and the trial will be reported
according to the Consolidated Standards of Reporting Tri-
als (CONSORT) Statement [20].
Participants
A total of 64 patients (16 per center) aged between 40
and 89 years with stable moderate to very severe COPD
(i.e., post-bronchodilator FEV1 < 80% of predicted), will
be included.
Exclusion criteria consist of: patients with asthma as pri-
mary diagnosis, cardiovascular, neuromuscular, and/or
skeletal diseases that are unstable and/or that may con-
tribute to exercise limitation or any other contraindication
to exercise; currently participating in a structured exercise
or pulmonary rehabilitation program or been involved in
pulmonary rehabilitation in the past 6months; experi-
enced a COPD exacerbation and/or change in medication
dosage/frequency in the past 6 weeks. Participants are
prohibited to participate in other organized training pro-
grams during the trial period but are encouraged to con-
tinue with normal everyday physical activity.
Procedure
Before commencing outcome assessment, all procedures
will be explained and the informed consent form will be
reviewed and signed. Participants will perform two test
visits (three if accepting a muscle biopsy) before the start
of the study and immediately following the 8-week inter-
vention period, with adequate recovery between tests and
test visits. The same tests and procedures will be used
across centers, and pre- and post-intervention assess-
ments will be performed in the same time of the day, with
strictly standardized procedures. A summary of study
visits and participant data collection schedule are pre-
sented in Fig. 1 (SPIRIT Figure), and the flow diagram for
the overall study in Fig. 2. Screening and enrollment are
planned to start in the spring of 2018 and continue until
the target sample size is reached. A 2-year recruitment
period is expected. The site investigator at each center will
be responsible for the enrollment of participants.
Sample size calculation
Multicenter trials involve a correlation in data, i.e., par-
ticipants from the same center are likely to be more
similar than subjects from other centers. As such, a
correlation potentially affects the statistical power of the
trial the sample size needs to be adjusted, often in-
creased, to account for the design of the study [21]. To
minimize the effect of using different centers, eligibility
criteria as well as design and delivery of training inter-
ventions are standardized across centers. Furthermore,
in an individually randomized trial that is stratified for
centers, similar to the present trial, the design effect is
estimated to be < 1 which involves a gain in power,
allowing a reduction in sample size rather than an in-
crease [21, 22]. Nevertheless, the sample size calculation
is performed with a design effect of 1 and is based on
the results from a resistance training meta-analysis on
healthy adults in which a group difference of 1.16 (SD
1.09) was seen on muscle function when comparing
NLPRT with RT [18]. Thus, based on an expected group
difference in effect size of 1.16 (SD 1.09) on muscle
function with a power of 80%, two-sided alpha of 0.05
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(including 15% drop-outs) 16 patients per group is re-
quired (32 in total). However, we plan to recruit a total
of 64 patients with an equal distribution of men and
women. The planned sample size (n = 64, including 15%
drop-out) will be sufficient to have power for subgroup
analysis based on sex (male and female).
Randomization and masking
A person not involved with either enrollment, assess-
ments nor training of participants will generate the
allocation sequence and assign participants to one of the
two interventions.
To prevent foreknowledge of treatment assignment
and to keep the allocation sequence concealed from
the participants and the researchers, group allocation
will be done after the completion of baseline and in-
clusion tests with a computer random-number gener-
ator. Individual randomization, stratified for centers
and sex, will be performed with a 1:1 allocation to
the intervention and control groups. The allocation
sequence will be kept in an opaque, sealed and
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure. Summary of data collection visits. *Performed at two
centers (Umeå and Quebec) at a separate third visit during baseline and follow-up assessments. NLPRT non-linear periodized resistance training,
RT resistance training, ISWT Incremental Shuttle Walk Test, ESWT Endurance Shuttle Walk Test, UULEX Unsupported Upper Limb Exercise Test,
60STS 60-s Sit to Stand Test, HRQoL health-related quality of life
Frykholm et al. Trials            (2019) 20:6 Page 4 of 13
stapled envelope and will be kept concealed until the
end of the outcome assessment. The envelope will be
made impermeable to intense light by using
aluminum foil inside and sealed using tamper-proof
labels.
The outcome assessors will be masked to group al-
location. Furthermore, the participants will be given
repeated instructions not to reveal their group alloca-
tion to the outcome assessors. In case of failure in
keeping the outcome assessor masked (i.e., a patient
reveals their group allocation), a second trained out-
come assessor will be available.
Due to the nature of the intervention neither partici-
pants nor instructors of the training sessions will be
masked during the intervention, the hypotheses of the
trial will, however, not be revealed to the participants be-
fore and during the trial. The data analysts will be
masked to group allocation.
Training interventions
Participants will be randomized to either NLPRT or RT of
leg press, shoulder flexion, calf press and chest press exer-
cises (three times per week for 8 weeks). The following
will be similar for both the NLPRT and the RT groups.
1. All exercises will be performed using training
equipment available at each participating center.
Leg press, chest press and calf press exercises will
be performed using available weight machines and
the shoulder flexion exercise will be performed
using free weights
2. Exercise order will be pre-determined: (1) leg press,
(2) shoulder flexion, (3) calf press and (4) chest
press. This exercise order will be used in order to
alternate between lower and upper-limb exercises
and between multiple- and single-joint exercises. All
exercises will be performed bilaterally
Fig. 2 Participant flow diagram
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3. Rest between exercises will be standardized to 4
min and all exercises will be performed using
dynamic repetitions with both concentric and
eccentric muscle actions. The speed of motion in
each exercise will be controlled by the breathing of
the participant, we expect a moderate exercise
velocity, i.e., 1–2:1–2 s in the concentric and the
eccentric phase, respectively
4. All sessions will be supervised and conducted by
local professionals using a group format, with
approximately two to four participants per group
5. Each session will span approximately 60 min
including a mandatory 5-min rest before and after
the training sessions. During this time, oxygen sat-
uration, heart rate, dyspnea and general fatigue
(rated on the Borg revised category ratio 0–10 scale
(Borg CR10) [23]), will be collected
6. Dyspnea, limb-muscle fatigue and exertion ratings
on Borg CR10, the later defined as “how heavy the
exercise felt,” will be collected immediately after
each set of exercise
7. Exercise volume for each training session = (number
of repetitions per set × sets per exercise × exercises
per session) will be reported
8. New 1 repetition max (RM) and multiple RM tests
will be performed three times during the 8-week
intervention period (after session 5, 10 and 15) in
order to optimize exercise loadings. If a 1-RM test is
lower than the prior 1 RM or if there is a mismatch
between calculated training load from the new 1 RM
and training load during the previous week, the
higher training load will be used and a new test will
be performed prior to the next training session to
minimize the impact of alterations in daily fitness
9. No general warm-up will be performed prior to ses-
sions but a specific warm-up set of 15 repetitions
using a load corresponding to 30% of 1RM prior to
each exercises will be performed within the NLPRT
and RT sessions
NLPRT
The primary objectives of the NLPRT program will be to
increase muscle strength as well as muscle endurance.
The NLPRT program will be designed based on the
structure shown in Fig. 3. The 8-week NLPRT program
will target various aspects of limb-muscle function by al-
ternating between the different intensity zones [24].
Number of sets, number of repetitions, intensities (% of
1 RM) and rest periods will be based on what is pre-
sented in Fig. 3.
Furthermore, the NLPRT program will be divided into
three phases, a base phase (1 week), an intermediate
phase (1 week) and an optimizing phase (6 weeks (of
which 2 weeks are optimized for limb-muscle strength
and 4 weeks optimized for limb-muscle endurance)). An
overview of the pre-planned NLPRT setup, including in-
formation on how exercises will be progressed, is seen in
Fig. 4. Within the NLPRT program, the first 4 weeks will
focus more on muscle strength (exercise zones C and D)
while the last 4 weeks will focus more on muscle endur-
ance (exercise zones A and B). Progression of exercise
will be symptom dependent and will be based on Borg
CR10 exertion and fatigue ratings.
RT
The primary objective of the RT group will be to in-
crease muscular strength. The RT program will be
performed in line with current guidelines, i.e., three
sets of 8–12 repetitions at an initial load equal to
60% of 1RM (similar to zone C [Fig. 3]) [9, 25] that
are recommended for increasing muscle strength in
patients with COPD [9]. Rest between sets will be 2
min. Progression of exercises, fixed 5% increase in
load, will be performance-based, i.e., an increase oc-
curs when an individual can perform 12 repetitions
on the current workload, on two consecutive training
sessions [9, 26]. An overview of the pre-planned
structure for the traditional resistance training group
is seen in Fig. 4.
Adherence to intervention
To promote participant retention, efforts will be made
to make training sessions in both groups enjoyable
for participants. This will include easy access to the
facility by the means of transportation preferred by
the participants, small training groups in a
Fig. 3 Structure for periodized resistance training [24]
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comfortable setting using equipment suitable for this
group of people, and personal monitoring from med-
ically educated instructors. To promote the number
of sessions attended during the intervention period,
the intervention period can be extended by maximum
1 week due to missed sessions.
The adherence to the intervention will be documented
by the instructor conducting the training sessions. In the
case that a participant misses a training session without
prior notice, the instructor will contact the participant
by phone on the same day.
Participant safety
Reasons for immediately stopping an outcome tests or
training session for people with COPD will include the
following: (1) chest pain, (2) intolerable dyspnea, (3) leg
cramps, (4) staggering, (5) diaphoresis and (6) pale or
ashen appearance [27]. The assessors and instructors are
trained to recognize these problems and to deliver the
appropriate intervention. Further, this will be reported
as an adverse event. If a participant experiences pain/
discomfort from the exercising limb during training no
progression will occur even if the participant reaches
Fig. 4 Pre-planned setup of the non-linear periodized resistance training (NLPRT) and resistance training (RT) program. *For < 20 repetition
sessions, adjustments will result in increases in intensity ranging between 2 and 10% [23]. †For ≥ 20 repetition sessions, adjustments will result in
increases in volume (+ 10 repetitions for lower extremity exercise and + 5 repetitions for upper extremity exercises). §A fixed increase in load of
5% will be added if 12 repetitions are performed in all sets in 2 consecutive sessions [9, 26]
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other requirements for progression in the NLPRT or RT
group, respectively. If pain prohibits execution of an ex-
ercise, this specific exercise will be removed.
Data collection, management and analysis
The assessors will have previous experience of the in-
cluded outcomes and formal training will be provided to
the instructors of the training programs. If necessary,
protocols for each measurement and exercise will be de-
veloped to assist instructors. These protocols will be
available on request from the principal investigator.
Screening tests and baseline characteristics A
pulmonary function test (spirometry), while being on the
participant’s usual bronchodilator therapy, will be ob-
tained according to guidelines [28]. Anthropometrics will
include height, weight and body mass index. To document
baseline level of physical activity, participants will also be
instructed to wear an accelerometer (DynaPort®,
McRoberts BV, The Netherlands), placed on the lower
back during seven consecutive days before the interven-
tion period. The quantity of physical activity will be
assessed using the median number of steps per day col-
lected on at least two consecutive weekdays over at least
8 h of daytime [29]. Primary and secondary outcome as-
sessments will be conducted at two (three if accepting a
biopsy) test occasions at weeks 0 and 9 (before and after
intervention). Before and directly after all physical tests,
the perception of dyspnea and muscle fatigue will be mea-
sured with the Borg CR10 [23] as commonly and reliably
used in patients with COPD [30–32].
Primary outcomes
Isotonic strength and endurance
Isotonic maximal strength (1 repetition maximum
(1RM)) and endurance test (maximum number of repeti-
tions performed at 45% of 1 RM) will be performed dur-
ing leg press, shoulder flexion, calf press and chest press
using a procedure earlier used in an untrained
middle-aged population [33]. All RM tests will be sepa-
rated by a 5-min rest period.
All tests will be performed using exercise equipment
that are available at each included center. Leg-press,
chest-press and calf press tests will be performed using
available weight machines and the shoulder flexion test
will be performed using free weights. The tests will be
performed in order to individualize progression and to
determine the effects of the training performed after the
8-week intervention period. 1RM is defined as the max-
imum load able to be lifted with good technique through
the full range of motion (ROM) [34]. The structure of all
1RM testing is designed so that a 1RM could be
achieved in 3–5 attempts. All 1RM test will be preceded
by a warm-up of 10 repetitions, using a light load,
performed from the start position to the end position in
each exercise. The start loading for 1RM testing will cor-
respond to a perceived resistance of 50–70% of 1RM
with gradual increases in each trial until 1RM is
achieved. The rate of the gradual increase in load is
dependent on the participant’s self-perceived capacity
and 3–5 min of rest will be used between trials. Lastly,
the settings and load of each exercise trial will be noted
in the protocol.
 Leg press will be tested with the participants placed in
a seated leg-press machine, adjusted so that the range
of movement (ROM) of the knee joint will be from
90° flexion to full extension without discomfort in hip
or ankle joints. Feet will be positioned shoulder-width
apart and fully in contact with the surface during the
whole ROM and arms held crossed over the chest.
The start position for the test will be with the knee
joint in 90° flexion. The placement of the feet will be
noted so that the pre- and post-intervention testing
will be done in the same position
 Shoulder flexion will be tested using dumbbells,
performed while seated on a bench with backrest
(120° hip angle) with both feet on the floor. Using
one dumbbell in each hand, the participant starts
with arms hanging towards the floor, then raises the
dumbbell, thumbs pointing upwards, with a fully
extended elbow using flexion of the shoulder in the
sagittal plane to a 120° shoulder flexion, defined by
when the participant can see their own elbow, and
returns to the start position. A string will be
attached in front of the participant to help
participants as well as evaluators to ensure that the
movement will be performed in the whole ROM
 Calf press will be tested using the same machine as
for the leg press. The feet are placed so that when
the participant’s knees are fully extended the legs are
aligned with the applied force from the machine.
The starting position will be with fully extended
knees and the whole sole of the feet on the surface
and the end position will be at full individual plantar
flexion. The placement of the feet will be noted so
that the pre- and post-intervention testing will be
done in the same position
 Chest press will be tested with the handlebars placed
at mid-sternum height and while the participant grips
the handles with the elbows at 90° flexion at sternum
height. The back should lie be firmly on the backrest
and both feet on the floor. When the participant
reaches full extension in the elbows, the end position
of the movement will be considered reached
For the multiple RM (limb-muscle endurance) test, the
settings and starting positions from the 1RM test will be
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used. Our multiple RM is defined as the maximum
number of repetitions able to be lifted with a good tech-
nique through the full ROM at an intensity correspond-
ing to 45% of 1 RM [34]. In order for training specificity,
an upper limit of 60 repetitions on the multiple RM test
will be used at baseline testing. If a participant exceeds
60 repetitions on a multiple RM test at baseline, the test
will be redone with a higher resistance. A maximum of
three tests will be performed. Test order will be
pre-determined: (1) leg-press, (2) shoulder flexion, (3)
calf press and (4) chest press. Warm-up will be one set
of 10 repetitions using 50% of the resistance to be used




Walking performance will be evaluated by the endurance
shuttle walk test (ESWT) performed in accordance to
guidelines, reported in meters or seconds [35, 36]. The
incremental shuttle walk test (ISWT) will be performed
in order to determine the correct walking speed for the
ESWT. The ISWT continues until the participant can no
longer continue or cannot keep up with the required
pace. The maximum duration of the test is 20 min [35].
The ESWT is a derivative of the ISWT, where patients
walk for as long as possible at a predetermined percent-
age of maximum walking performance as assessed by
the ISWT [36]. One test is sufficient to obtain a reliable
measure [35]. The ESWT are responsive to changes with
interventions in patients with COPD [37].
During the 60STS, participants will be instructed to
fully stand up and sit down as fast as possible, as
many times as possible within 60 s. Arms will be held
folded across the chest with feet remaining in full
contact with the floor. The number of repetitions per-
formed within 60 s will be collected. Chair height will
be 48 cm or low enough to allow both feet to be in
full contact with the floor. The test is reliable, valid
and responsive for measuring functional exercise cap-
acity for people with COPD [38, 39].
The UULEX test is performed seated. Start position of
the test is seated, with the plastic bar (0.2 kg) held with
both hands at shoulder width, resting on the proximal
parts of the thighs of the participant. Participants will
then be asked to raise it from hip to the UULEX
eight-level chart for 2 min at the first level and there-
after, 1 min at each level with a cadence of 30 move-
ments per min. If a patient reaches the highest level, the
plastic bar will be replaced by a heavier one every min.
There are five different bar weights (0.2, 0.5, 1, 1.5, 2 kg)
and participants will continue on the highest level until
symptom limitation [40].
Isometric quadriceps strength and endurance
In addition to isotonic measurements of muscle strength
and endurance, we will also perform isometric measure-
ments, since the different techniques (isotonic versus
isometric) might differ with regard to clinical relevance
and responsiveness to training [41].
Isometric testing will be performed either using a
Biodex Multi-Joint System 3 or 4 (Biodex Corp., Shirley,
NY, USA) or a fixed-strain gauge (Biopac System inc,
Goleta, CA, USA), depending on the availability of sys-
tem at each respective center.
After a warm-up of two to three submaximal contrac-
tions, five maximal trials will be performed with each
contraction sustained for 5 s. One-minute rests will be
given between repeated trials to minimize muscle fa-
tigue. Quadriceps maximal voluntary contraction (MVC)
torque will be recorded in Newton meters (Nm) for each
contraction. Thus, for strain-gauge measurements the
Nm will be calculated by dividing force in Newtons by
the length of the lever arm. The peak of the two best re-
producible contractions (within a 5% coefficient of vari-
ation) will be reported as the test result.
After a 15-min rest period, the muscle strength test
will be followed by an isometric measurement of quadri-
ceps endurance. Participants will be instructed to main-
tain a tension representing 60% of their MVC until
exhaustion. A computer screen will serve as a feedback
mechanism to help subjects maintain the determined
submaximal tension. Subjects will be strongly encour-
aged to pursue until tension drop under 50% MVC. The
time to fatigue, defined as the time at which the isomet-
ric contraction reached 50% MVC, will be used as a
measure of muscle endurance.
HRQoL
The self-administered version of the chronic respiratory
disease questionnaire (CRQ-SA) [42] will be used to as-
sess HRQoL. The CRQ is a widely used disease-specific
questionnaire to assess symptoms of people with COPD.
The CRQ is valid and responsive to treatment [43], and
has previously been used to evaluate the effects of resist-
ance training [31, 44].
Dyspnea
The Borg CR10 will be used to quantify the level of dys-
pnea during exercise training and tests while general
dyspnea in daily life will be evaluated using the dyspnea
subscale of the CRQ.
Number of responders
The total amount of responders, i.e., defined as a re-
sponse over the known minimal detectable change/or
minimal important difference for included test(s), will be
determined and compared. For example, the minimal
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important difference after rehabilitation is suggested to
be 177 s for the ESWT [45] and three repetitions for the
60 STS [46].
Feasibility
Feasibility of the training programs will be assessed and
compared between groups from the attendance rate,
duration, satisfaction, drop-outs as well as occurrence
and severity of any adverse events.
 Attendance rate will be evaluated by calculating the
number of attended sessions divided by total
number of sessions
 Duration of exercise sessions will be evaluated by
measuring the time taken to complete an exercise
session, including the 5-min mandatory rest periods
before and after the exercise session
 Patient satisfaction with the exercise regimens will
be recorded by adapting an existing patient
satisfaction questionnaire previously used for single-
legged cycling [47].
 The number of drop-outs will be collected and com-
pared across resistance regimens
 Information about adverse events will be collected for
both exercise protocols. Two independent
pulmonologists and one physiotherapist whom will
not be involved in the study will evaluate the adverse
events. The severity of the adverse events will be
assessed and rated into four different categories: (1)
minor and temporary, (2) serious symptoms (potential
risk of severe injury or life threatening), (3) manifest
injury or disease and (4) death, as previously used
[48]. An adverse event rate will be calculated for each
patient as the total number of sessions during which
any adverse events occurred divided by the total
number of attended sessions
Intramuscular adaptations
Vastus lateralis muscle biopsies are sampled in Umeå
(10–16 pre/post biopsies) and in Quebec (10–16 pre/
post biopsies) to assess muscle fiber size, expression of
slow and fast subtypes of contractile myosin heavy chain
isoforms in fibers, oxidative (CS, EC 4.1.3.7) and glyco-
lytic (LDH, EC 1.1.1.27) enzyme activities as well as
capillarization (capillary density, number of capillaries
around fiber and capillaries around fibers relative to its
cross-sectional area).
Possible correlations between capillary parameters,
fiber phenotype composition, fiber cross-sectional area,
enzymatic activity and other outcome measures, such as
quadriceps muscle strength and endurance, after the re-
sistance training interventions will be evaluated.
Data management
All data will be coded and reported on a group level. It
will not be possible to identify specific individuals in the
trial. The participants’ identities will only be known by
the research group at respective center and the principal
investigator.
The REDCap (Research Electronic Data Capture)
Survey, a secure, Health Insurance Portability and
Accountability Act compliant, web-based survey applica-
tion will be used to manage and store project data [49].
To ensure confidentiality, data dispersed to project team
members will be blinded of any identifying participant
information. All records that contain names or other
personal identifiers, such as locator forms and informed
consent forms, will be stored separately from study re-
cords identified by code number at local research cen-
ters, respectively. All local databases will be secured with
password-protected access systems.
Statistics
The primary analyses will be an intention-to-treat analysis
(including all participants randomized) in addition, a
complete case population (participants with complete out-
come measurements independent on adherence to inter-
vention), and a per-protocol analysis (defined as at least
80% overall attendance rate as well as no exacerbations
during the last 2 weeks prior to follow-up assessment) will
be performed. Missing data will be imputed in the
intention-to-treat analysis using multiple imputation as-
suming data is missing at random conditional on partici-
pant severity of disease and history of exacerbations. This
is because severity of disease and history of exacerbations
are known risk factors for future exacerbations and may
affect adherence to the training protocol [28].
Mixed models will be used for analysis of data with
individuals at level 1 and center at level 2. Estimates of ef-
fect sizes will be computed using Cohen’s d (d = difference
in group means/error SD within). Calculated as the
difference between predicted means from the final
mixed-effects model for a given pair of groups divided by
the estimated within-group error SD in the model with
the estimated value of 2σ2e , where σ
2
e is the residual vari-
ance. To judge the quality of the model we will analyze
the residuals. For responsiveness, values of 0.20, 0.50
and ≥ 0.80 correspond to small, moderate and large re-
sponsiveness, respectively [50].
We will consider two-sided p values < 0.05 as statisti-
cally significant for the primary outcomes without cor-
rection for a multiplicity of tests assuming that each test
represents an independent function based on the specifi-
city principle of training [26]. Relationships between pa-
rameters will be evaluated using Pearson correlation
coefficients. The strength of the correlation coefficients
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will be categorized as low (0–0.25), moderate (> 0.25–
0.50), strong (> 0.50–0.75), very strong (> 0.75).
Pre-planned subgroup analyses are differences between
men and women. Statistical analysis will be performed
using the statistical package SPSS 23.1.
Amendments
Any modifications to the protocol which may impact on
the conduct of the study, potential benefit of the patient
or may affect patient safety, including changes of study
objectives, study design, patient population, sample sizes,
study procedures or significant administrative aspects
will require a formal amendment to the protocol. Such
amendments will be agreed upon by the research group
with the final decision by the principal investigator, and,
if needed, approved by the Local Ethics Committees.
Administrative changes of the protocol (e.g., minor cor-
rections and/or clarifications) that have no effect on how
the study is conducted will be agreed upon by the research
group with the final decision by the principal investigator
and documented and presented upon publication.
Discussion
Improving limb-muscle function is an important thera-
peutic goal in the management of patients with COPD
for which resistance training often is recommended over
other available exercise training modalities [8–10]. Even
so, the optimal resistance training prescription for
people with COPD remains to be determined [8].
Among healthy adults, periodized resistance training has
been found to increase limb-muscle strength significantly
more than traditional RT [17]. Periodization, which repre-
sents a planned variation of resistance training variables,
could be done in several different ways, e.g., using either
linear-, block- or non-linear, (undulated) periodization
strategies. In people with COPD, the latter strategy has
been shown to lead to larger benefits in comparison to
traditional, non-periodized training when applied during
aerobic exercise training [16]. However, whether the con-
cept of non-linear periodization of training variables
would be beneficial also during resistance training in
people with COPD remains to be determined.
The proposed trial will provide new knowledge to this
research area by investigating and comparing the feasi-
bility and effects of NLPRT compared to traditional RT.
If, as we hypothesize, NLPRT produces larger physio-
logical adaptations than RT, this project may influence
the prescription of resistance training in patients with
COPD. The NLPRT approach used within the present
project is not only designed to optimize the effects of ex-
ercise training on limb-muscle strength, but also on
limb-muscle endurance by targeting multiple aspects of
limb-muscle function commonly seen among patients
with COPD [1]. Furthermore, the present project will
also include assessment of potential intramuscular adapta-
tions following two different resistance training ap-
proaches. This is highly warranted [51] and should
provide novel insight in understanding the role of resist-
ance training as a countermeasure of limb-muscle dys-
function in COPD. The results of this project will also
provide novel information about the feasibility of
utilizing the concept of NLPRT in clinical settings,
potentially providing a highly effective and feasible
resistance-training strategy that could be easily imple-
mented in clinical practice.
Trial registration
The clinical trial has been registered before the enroll-
ment of the first participant. Date of trial registration: 13
April 2018. ClinicalTrials.gov identifier: NCT03518723.
The recruitment will begin in 2018 and will continue
until sufficient power is reached.
Trial status
The trial is in the phase of recruiting participants at the
time of submission of this protocol on 9 May 2018.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents. (DOC 120 kb)
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